XML 38 R25.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2

SHAREHOLDERS' EQUITY (Tables)

3 Months Ended

Mar. 31, 2024

Share-based Payment Arrangement [Abstract]

Schedule of employee options activity

		Number				Weighted average exercise price				Weighted average remaining contractual life (years)				Aggregate intrinsic value (in thousands)
Options outstanding as of December 31, 2023			4,723			$	259.73				4.39			$	-
Granted			-				-				-				-
Exercised			-				-				-				-
Forfeited			-				-				-				-
Options outstanding as of March 31, 2024			4,723			$	259.73				4.14			$	-
Options exercisable as of March 31, 2024			4,723			$	259.73				4.14			$	-

Schedule of employee RSUs activity

		Number of shares underlying outstanding RSUs				Weighted- average grant date fair value
Unvested RSUs as of December 31, 2023			538,885			$	6.07
Granted			-				-
Vested			(14,704	)			6.03
Forfeited			-				-
Unvested RSUs as of March 31, 2024			524,181			$	6.07

Schedule of options and RSUs outstanding

Range of exercise price			Options and RSUs outstanding as of March 31, 2024				Weighted average remaining contractual life (years) (1)				Options outstanding and exercisable as of March 31, 2024				Weighted average remaining contractual life (years) (1)
RSUs only				524,181				-				-				-
$37.6				1,774				4.99				1,774				4.99
$178.5 - $236.3				1,845				4.10				1,845				4.10
$350 - $367.5				887				3.21				887				3.21
$1,277.5 - $3,634.8				217				1.39				217				1.39
				528,904				4.14				4,723				4.14

(1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.

Schedule of warrants outstanding and exercisable

Issuance date		Warrants outstanding				Exercise price per warrant				Warrants outstanding and exercisable			Contractual term
		(number)								(number)
December 31, 2015 (1)			681			$	52.50				681		See footnote (1)
December 28, 2016 (2)			272			$	52.50				272		See footnote (1)
April 5, 2019 (3)			58,350			$	35.98				58,350		October 7, 2024
April 5, 2019 (4)			7,001			$	45.52				7,001		April 3, 2024
June 5, 2019, and June 6, 2019 (5)			209,235			$	52.50				209,235		June 5, 2024
June 5, 2019 (6)			12,552			$	65.63				12,552		June 5, 2024
June 12, 2019 (7)			59,523			$	42.00				59,523		December 12, 2024
June 10, 2019 (8)			7,142			$	52.50				7,142		June 10, 2024
February 10, 2020 (9)			4,054			$	8.75				4,054		February 10, 2025
February 10, 2020 (10)			15,120			$	10.94				15,120		February 10, 2025
July 6, 2020 (11)			64,099			$	12.32				64,099		January 2, 2026
July 6, 2020 (12)			42,326			$	15.95				42,326		January 2, 2026
December 8, 2020 (13)			83,821			$	9.38				83,821		June 8, 2026
December 8, 2020 (14)			15,543			$	12.55				15,543		June 8, 2026
February 26, 2021 (15)			780,095			$	25.20				780,095		August 26, 2026
February 26, 2021 (16)			93,612			$	32.05				93,612		August 26, 2026
September 29, 2021 (17)			1,143,821			$	14.00				1,143,821		March 29, 2027
September 29, 2021 (18)			137,257			$	17.81				137,257		September 27, 2026
			2,734,504								2,734,504

(1) Represents warrants for ordinary shares issuable upon an exercise price of $52.50 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited (“Kreos”) in connection with a loan made by Kreos to the Company and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly owned subsidiary of the Company, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of March 31, 2024.

(2) Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms.

(3) Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in April 2019.

(4) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s April 2019 registered direct offering.

(5) Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019, and June 6, 2019, respectively.

(6) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 warrant exercise agreement and concurrent private placement of warrants.

(7) Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019.

(8) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 registered direct offering and concurrent private placement of warrants.

(9) Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. As of March 31, 2024, 534,300 warrants were exercised for total consideration of $4,675,125. During the three months that ended March 31, 2024, no warrants were exercised.

(10) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. As of March 31, 2024, 32,880 warrants were exercised for total consideration of $359,625. During the three months that ended March 31, 2024, no warrants were exercised.

(11) Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in July 2020. As of March 31, 2024, 288,634 warrants were exercised for total consideration of $3,556,976. During the three months that ended March 31, 2024, no warrants were exercised.

(12) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s July 2020 registered direct offering.

(13) Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in December 2020. As of March 31, 2024, 514,010 warrants were exercised for total consideration of $4,821,416. During the three months that ended March 31, 2024, no warrants were exercised.

(14) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. As of March 31, 2024, 32,283 warrants were exercised for total consideration of $405,003. During the three months that ended March 31, 2024, no warrants were exercised.

(15) Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in February 2021.

(16) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2021 private placement.

(17) Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in September 2021.

(18) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering.

Schedule of non-cash share-based compensation expense

		Three Months Ended March 31,
		2024				2023
Cost of revenues		$	4			$	(2)
Research and development, net			46				32
Sales and marketing			111				81
General and administrative			220				193
Total		$	381			$	304

X

- References

No definition available.

+ Details

Name:	us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-1

+ Details

Name:	us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration